A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular TherapiesA Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies

Trial purpose

Long-term follow-up

Tumor type

Multi-Cancer

Age

18+

Summary

All participants with haematological and solid cancers who are enrolled in a parent study and were exposed to allgeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.

Participants who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of participants with progressive disease or who receive a subsequent line of anti-cancer therapy) in the parent study may enroll in this LTFU study.

This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapy.

Conditions

This trial is treating people with blood or solid cancers who have been in a previous CRISPR CAR T study